Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- NBI Files for Micardis, Amlodipine, Diuretic Triple Combination Agents
August 18, 2015
- ASCO Immunotherapy Roundup - 7: Patient Group Hails Dawn of New Cancer Treatment Era
August 14, 2015
- Otsuka’s US Subsidiary Wins Patent Lawsuit over PBA Treatment
August 14, 2015
- Japan’s Diabetes Market to Exceed 600 Billion Yen in 2023: Fuji Keizai
August 14, 2015
- Kyowa Kirin Looks to Derive 40% of Sales Overseas by 2020, Split from Holdings Firm Won’t Happen: Pres.
August 13, 2015
- Hospira Japan’s Generic Oxaliplatin Approved for Gastric Cancer
August 13, 2015
- Ethical Drug Sales Up 9.8% in June: Crecon Report
August 13, 2015
- INCJ Invests 600 Million Yen in Drug Discovery Venture Founded by Tokyo Medical and Dental Univ.
August 12, 2015
- ASCO Immunotherapy Roundup - 6: CAR T-Cell Therapy Another Hot Field in Immuno-Oncology
August 12, 2015
- Quintiles to Set Up Unit for Medical Devices and Regenerative Medicines
August 12, 2015
- Biogen Japan Expects Continued Growth Past 2020 through Major New Drugs
August 11, 2015
- Long-Acting Injectable Version of Abilify Entering Accelerated Growth Phase: Pres. Higuchi of Otsuka Holdings
August 11, 2015
- Sublingual Immunotherapy Tablet for Pollinosis Shows Efficacy in PII/PIII Study in Japan: Torii
August 11, 2015
- Denki Kagaku Kogyo to Acquire Germany’s Biopharma Icon Genetics
August 11, 2015
- Drug Wholesalers Suffer 1st Sales Drop since 1997
August 10, 2015
- Sumitomo Dainippon Will Be Able to Cover the Loss of Long-Listed Drug Sales: President
August 10, 2015
- Pharmaceutical Sales Down 2.4% in 1st Half Due to Loss of Patent Protection for Abilify in US: Otsuka Holdings
August 10, 2015
- Sosei’s UK Subsidiary, AZ Partner for Development of Cancer Immunotherapies
August 10, 2015
- ASCO Immunotherapy Roundup - 5: Merck & Co. Discovers New Biomarkers for Keytruda
August 7, 2015
- Sanofi Files NDA for Hypercholesterolemia Treatment Alirocumab in Japan
August 7, 2015
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…